{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:59:13Z","timestamp":1793656753987,"version":"4.5.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>One-year monitoring of patients receiving intraperitoneal (IP) <jats:sup>212<\/jats:sup>Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eighteen patients with relapsed intra-abdominal human epidermal growth factor receptor-2 expressing peritoneal metastases were treated with a single IP infusion of <jats:sup>212<\/jats:sup>Pb-TCMC-trastuzumab, delivered &lt;4 h after 4 mg\/kg IV trastuzumab. Seven tumor markers were studied for correlation with outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six dose levels (7.4, 9.6, 12.6, 16.3, 21.1, 27.4 MBq\/m<jats:sup>2<\/jats:sup>) were well tolerated with early possibly agent-related adverse events being mild, transient, and not dose dependent. These included asymptomatic, abnormal laboratory values. No late renal, liver, cardiac, or other toxicity was noted up to 1 year. There were no clinical signs or symptoms of an immune response to <jats:sup>212<\/jats:sup>Pb-TCMC-trastuzumab, and assays to detect an immune response to this conjugate were negative for all tested. Tumor marker studies in ovarian cancer patients showed a trend of decreasing Cancer antigen 72-4 (CA 72-4) aka tumor-associated glycoprotein 72 (TAG-72) and tumor growth with increasing administered radioactivity. Other tumor markers, including carbohydrate antigen (CA125), human epididymis protein 4 (HE-4), serum amyloid A (SAA), mesothelin, interleukin-6 (IL-6), and carcinoembryonic antigen (CEA) did not correlate with imaging outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>IP <jats:sup>212<\/jats:sup>Pb-TCMC-trastuzumab up to 27 MBq\/m<jats:sup>2<\/jats:sup> seems safe for patients with peritoneal carcinomatosis who have failed standard therapies. Serum TAG-72 levels better correlated to imaging changes in ovarian cancer patients than the more common tumor marker, CA125.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000353","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:52:03Z","timestamp":1480524723000},"page":"716-721","source":"Crossref","is-referenced-by-count":98,"title":["Safety and Outcome Measures of First-in-Human Intraperitoneal \u03b1 Radioimmunotherapy With 212Pb-TCMC-Trastuzumab"],"prefix":"10.1097","volume":"41","author":[{"given":"Ruby F.","family":"Meredith","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien J.","family":"Torgue","sequence":"additional","affiliation":[{"name":"AREVA Med, Plano, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania A.","family":"Rozgaja","sequence":"additional","affiliation":[{"name":"AREVA Med, Plano, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen P.","family":"Banaga","sequence":"additional","affiliation":[{"name":"AREVA Med, Plano, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty W.","family":"Bunch","sequence":"additional","affiliation":[{"name":"Gynecology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Gynecology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Straughn","sequence":"additional","affiliation":[{"name":"Gynecology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Dobelbower","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1471-0528.1989.tb03251.x","article-title":"Intraperitoneal radioimmunotherapy for ovarian cancer","volume":"96","author":"Stewart","year":"1989","journal-title":"BJOG"},{"key":"R3-20230903","first-page":"36","article-title":"Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer","volume":"26","author":"Meredith","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/1097-0142(19920201)69:3<741::AID-CNCR2820690322>3.0.CO;2-G","article-title":"Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer","volume":"69","author":"Vergote","year":"1992","journal-title":"Cancer"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/ijc.22663","article-title":"Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival","volume":"120","author":"Oei","year":"2007","journal-title":"Int J Cancer"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of {alpha}-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fonc.2013.00324","article-title":"The potential and hurdles of targeted alpha therapy\u2014clinical trials and beyond","volume":"3","author":"Elgqvist","year":"2014","journal-title":"Front Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/1931153a0","article-title":"Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-kV. x- and 200-kV. X-radiation","volume":"193","author":"Barendsen","year":"1962","journal-title":"Nature"},{"key":"R9-20230903","first-page":"1","article-title":"MIRD monograph\u2014radiobiology and dosimetry for radiopharmaceutical therapy with alpha-particle emitters","volume":"56","author":"Allen","year":"2015","journal-title":"J Nucl Med"},{"key":"R10-20230903","first-page":"397","article-title":"Relative biological effectiveness for efficacy and toxicity in leukemia patients of the alpha-particle emitter, bismuth-213","volume":"21","author":"Sgouros","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood"},{"key":"R12-20230903","first-page":"255","article-title":"Targeted alpha anticancer therapies: update and future prospects","volume":"8","author":"Allen","year":"2014","journal-title":"Biologics"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood.V126.23.3794.3794","article-title":"Phase I trial of targeted alpha-particle immunotherapy with actinium-225-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML)","volume":"126","author":"Jurcic","year":"2015","journal-title":"Blood"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4161\/cbt.4.12.2251","article-title":"Intralesional targeted alpha therapy for metastatic melanoma","volume":"4","author":"Allen","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal {alpha}-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab\u2019)2\u2014a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J Nucl Med"},{"key":"R17-20230903","first-page":"12","article-title":"Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients","volume":"29","author":"Meredith","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2967\/jnumed.114.143842","article-title":"Dose escalation and dosimetry of first-in-human \u03b1 radioimmunotherapy with 212 Pb-TCMC-trastuzumab","volume":"55","author":"Meredith","year":"2014","journal-title":"J Nucl Med"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2015.07.005","article-title":"Absorbed doses and risk estimates of (211)At-MX35 F(ab\u2019)2 in intraperitoneal therapy of ovarian cancer patients","volume":"93","author":"Cederkrantz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20230903","first-page":"557","article-title":"Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2","volume":"20","author":"Milenic","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1158\/1078-0432.CCR-08-0256","article-title":"Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease","volume":"14","author":"Milenic","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"5, 1","DOI":"10.4161\/mabs.2.5.13054","article-title":"Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials","volume":"2","author":"Milenic","year":"2010","journal-title":"MAbs"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph8030416","article-title":"Toxicological studies of 212Pb intravenously or intraperitoneally injected into mice for a phase 1 trial","volume":"8","author":"Milenic","year":"2015","journal-title":"Pharmaceuticals"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJM197107152850302","article-title":"Demonstration of an antigen common to several varieties of neoplasia","volume":"285","author":"Lo Gerfo","year":"1971","journal-title":"N Engl J Med"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers","volume":"26","author":"Soletormos","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 3","key":"R27-20230903","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jcp.2004.018077","article-title":"The role of CA125 in clinical practice","volume":"58","author":"Moss","year":"2005","journal-title":"J Clin Pathol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","article-title":"Development of a multimarker assay for early detection of ovarian cancer","volume":"28","author":"Yurkovetsky","year":"2010","journal-title":"J Clin Oncol"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejogrb.2015.09.008","article-title":"Clinical value of human epididymis protein 4 and the risk of ovarian malignancy algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages","volume":"194","author":"Kotowicz","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00432-009-0755-5","article-title":"Phase II biomarker trial of a multimarker diagnostic for ovarian cancer","volume":"136","author":"Edgell","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"R32-20230903","first-page":"795","article-title":"Ovarian cancer biomarkers: current options and future promise","volume":"6","author":"Coticchia","year":"2008","journal-title":"JNCCN"},{"key":"R33-20230903","first-page":"163","article-title":"The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer","volume":"34","author":"Qiao","year":"2013","journal-title":"Eur J Gynaecol Oncol"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1757-2215-6-44","article-title":"The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer","volume":"6","author":"Anastasi","year":"2013","journal-title":"J Ovarian Res"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1757-2215-6-29","article-title":"Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4","volume":"6","author":"O\u2019Shannessy","year":"2013","journal-title":"J Ovarian Res"},{"key":"R36-20230903","first-page":"171","article-title":"Biomarkers for early detection of ovarian cancer","volume":"9","author":"Nguyen","year":"2013","journal-title":"Womens Health"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nucmedbio.2016.04.001","article-title":"Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates","volume":"43","author":"Kasten","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","article-title":"Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens","volume":"4","author":"Cramer","year":"2011","journal-title":"Cancer Prev Res"},{"key":"R40-20230903","first-page":"457","article-title":"Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer","volume":"36","author":"Dikmen","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"key":"R41-20230903","first-page":"260","article-title":"Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer","volume":"36","author":"Salmena","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"18641","DOI":"10.18632\/oncotarget.4080","article-title":"Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers","volume":"6","author":"Seagle","year":"2015","journal-title":"Oncotarget"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13048-014-0109-z","article-title":"Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes","volume":"7","author":"Tamir","year":"2014","journal-title":"J Ovarian Res"},{"key":"R44-20230903","first-page":"855","article-title":"Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis","volume":"20","author":"Wu","year":"2015","journal-title":"J BUON"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1369\/jhc.2010.956821","article-title":"Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis","volume":"58","author":"Urieli-Shoval","year":"2010","journal-title":"J Histochem Cytochem"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3802\/jgo.2015.26.1.46","article-title":"Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings","volume":"26","author":"Wilailak","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0046-8177(86)80041-7","article-title":"Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens","volume":"17","author":"Johnston","year":"1986","journal-title":"Hum Pathol"},{"key":"R49-20230903","first-page":"995","article-title":"Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3","volume":"76","author":"Thor","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"R50-20230903","first-page":"3118","article-title":"Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3","volume":"46","author":"Thor","year":"1986","journal-title":"Cancer Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201807000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:08:55Z","timestamp":1693710535000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201807000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000353","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}